Little is known about the prognostic significance of muscle loss for allogeneic hematopoietic stem cell transplantation (allo-HCT). We retrospectively analyzed consecutive patients who received allo-HCT from 2013 to 2015. All patients underwent computed tomography (CT) imaging and bioelectrical impedance analysis (BIA) within 30 days before allo-HCT. Skeletal muscle area (cm2) at the third lumbar vertebra level on CT imaging and skeletal muscle mass (kg) measured by BIA were normalized by height in meters squared (m2) to calculate the skeletal muscle area index (SMI) and skeletal muscle mass index (SMMI). SMI and SMMI were significantly correlated (r = 0.744; P < 0.001). The cumulative incidence of 1-year non-relapse mortality (NRM) was significantly higher in patients with low SMI than high SMI (17% versus 0%, respectively; P = 0.023). Overall survival was shorter in patients with low SMI than high SMI (56% versus 93%, respectively; P < 0.001). In univariate analysis, low SMI was associated with increased risk of NRM (HR 7.46; 95% CI 1.05-52.98; P = 0.044), and in multivariate analysis it was associated with higher overall mortality (HR 5.35; 95% CI 1.71-16.72; P = 0.004). These results suggest that low muscle mass is an independent predictor of mortality after allo-HCT.

中文翻译：

---

低的移植前骨骼肌质量对造血干细胞移植患者生存结局的预后意义。

关于异基因造血干细胞移植（allo-HCT）的肌肉丢失对预后的意义知之甚少。我们回顾性分析了2013年至2015年连续接受异基因HCT的患者。所有患者在异基因HCT之前的30天内接受了计算机断层扫描（CT）成像和生物电阻抗分析（BIA）。通过CT成像将第三腰椎水平的骨骼肌面积（cm2）和通过BIA测量的骨骼肌质量（kg）通过以米平方（m2）为单位的身高归一化，以计算骨骼肌面积指数（SMI）和骨骼肌质量指数（SMMI）。SMI和SMMI显着相关（r = 0.744； P <0.001）。低SMI患者的1年非复发死亡率（NRM）累积发生率显着高于高SMI患者（分别为17％和0％； P = 0.023）。低SMI患者的总生存期短于高SMI患者（分别为56％和93％； P <0.001）。在单变量分析中，低SMI与NRM风险增加相关（HR 7.46; 95％CI 1.05-52.98; P = 0.044），在多变量分析中，它与较高的整体死亡率相关（HR 5.35; 95％CI 1.71-16.72）。 ； P = 0.004）。这些结果表明，低肌量是异源HCT后死亡率的独立预测因子。